2023 World Conference on Lung Cancer (Posters)-EP07.05. Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease

EP07.05. Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and toxicity of Stereotactic Body Radiotherapy (SBRT) in patients with early-stage non-small cell lung cancer (ES-NSCLC) and interstitial lung disease (ILD). The medical records of 57 patients who underwent SBRT between 2009 and 2019 were retrospectively reviewed. The most common SBRT dose was 60 Gy in 4 fractions.<br /><br />The results showed that patients with ES-NSCLC and ILD had a poor prognosis and a high incidence of treatment-related lung toxicity after SBRT. During the follow-up period, 11 patients developed grade 3 or higher radiation-induced pneumonitis, and 34 patients died. The most common cause of death was lung cancer, followed by other lung diseases such as pneumonitis and exacerbation of ILD.<br /><br />The rates of 2-year freedom from local recurrence, progression-free survival, and overall survival were 70.3%, 32.5%, and 50.9%, respectively. Despite the toxicities associated with SBRT, the authors suggest that cancer-directed treatment should be considered for these patients due to the high incidence of lung cancer progression as the cause of death.<br /><br />In conclusion, SBRT in ES-NSCLC patients with ILD is associated with a significant risk of lung toxicity and treatment-related mortality. However, given that lung cancer progression is the most common cause of death in these patients, the authors recommend considering cancer-directed treatment despite its toxicities. Further research is warranted to better understand the outcomes and benefits of NSCLC treatment in this patient population.

Asset Subtitle

Young Seob Shin

Meta Tag

Speaker Young Seob Shin

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

Stereotactic Body Radiotherapy

SBRT

non-small cell lung cancer

NSCLC

interstitial lung disease

ILD

toxicity

prognosis

radiation-induced pneumonitis

lung cancer progression